The ProactiveMolecular Risk Classifier for Endometrial Cancer (ProMisE) algorithm applies POLE mutation, p53 and MMR protein expression analyses to sequentially assign first the MMR deficient group, then POLE mutant, and finally aberrant p53 cases; the remaining tumors are categorized as p53 normal [6,7]. The gene discussed is TP53; the disease is endometrial cancer.